The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Update on ETCTN P10500, a Phase I study of tazemetostat plus belinostat for the treatment of R/R NHL
Jennifer Amengual, MD, Columbia University Herbert Irving Comprehensive Cancer Center, New York City, NY, provides insight into the results of a Phase I clinical trial (NCT05627245) of tazemetostat plus belinostat for the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Dr Amengual highlights that the combination of these agents is well-tolerated, with only one dose-limiting toxicity (DLT) reported, and shows promising early signs of response, particularly in patients with T-cell lymphoma. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
